REVELATION BIOSCIENCES INC
For the period ended Dec 31, 2024. Filed Mar 6, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 6, 2025
REVB$3.94-4.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity (Deficit)
| Series A Preferred Stock · Common Stock · Additional Paid-in · Accumulated · Total Stockholders’ | |||||||
|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Capital | Deficit | Equity | |
| Balance as of December 31, 2022 (as previously reported) | 1 | $— | 77,375 | $77 | $26,399,224 | $(25,346,848) | $1,052,453 |
| Retrospective application of reverse recapitalization | — | — | (72,540) | (72) | 72 | — | — |
| Reverse stock split fractional stock round up | — | — | (23) | — | — | — | — |
| Balance at December 31, 2022 | 1 | $— | 4,812 | $5 | $26,399,296 | $(25,346,848) | $1,052,453 |
| Redemption of Series A Preferred Stock | (1) | — | — | — | — | — | — |
| Issuance of common stock from the February 2023 Public Offering | — | — | 6,017 | 5 | 33,469 | — | 33,474 |
| Class C Pre-Funded Warrants exercise | — | — | 699 | 1 | 33 | — | 34 |
| Alternative cashless exercise of Class C Common Stock Warrants | — | — | 4,948 | 5 | 5,526,282 | — | 5,526,287 |
| RSU awards issued | — | — | 8 | — | — | — | — |
| Stock-based compensation expense | — | — | — | — | 155,721 | — | 155,721 |
| Net loss | — | — | — | — | — | (120,254) | (120,254) |
| Balance as of December 31, 2023 | — | $— | 16,484 | $16 | $32,114,801 | $(25,467,102) | $6,647,715 |
| Balance as of December 31, 2023 (as previously reported) | — | $— | 264,537 | $265 | $32,114,552 | $(25,467,102) | $6,647,715 |
| Retrospective application of reverse recapitalization | — | — | (248,029) | (249) | 249 | — | — |
| Reverse stock split fractional stock round up | — | — | (24) | — | — | — | — |
| Balance at December 31, 2023 | — | $— | 16,484 | $16 | $32,114,801 | $(25,467,102) | $6,647,715 |
| Issuance of common stock from the February 2024 Public Offering | — | — | 8,029 | 8 | 5,417,045 | — | 5,417,053 |
| Class D Pre-Funded Warrants exercise | — | — | 77,282 | 78 | 49 | — | 127 |
| Alternative cashless exercise of Class C Common Stock Warrants | — | — | 212 | — | 57,589 | — | 57,589 |
| Common stock issued for services | — | — | 653 | 1 | 24,999 | — | 25,000 |
| Class D Common Stock Warrants exercises | — | — | 6,312 | 6 | 241,384 | — | 241,390 |
| Class D Warrant Inducement exercises | — | — | 159,249 | 159 | 3,501,117 | — | 3,501,276 |
| Class E Common Stock Warrant Inducement exercises | — | — | 254,002 | 254 | 3,687,664 | — | 3,687,918 |
| Stock-based compensation expense | — | — | — | — | 168,850 | — | 168,850 |
| Net loss | — | — | — | — | — | (15,038,536) | (15,038,536) |
| Balance as of December 31, 2024 | — | $— | 522,223 | $522 | $45,213,498 | $(40,505,638) | $4,708,382 |
| Year EndedDecember 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(15,038,536) | (120,254) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 168,850 | 155,721 |
| Issuance of common stock for services | 25,000 | — |
| Depreciation expense | 27,923 | 25,049 |
| Change in fair value of warrant liability | (81,441) | (8,328,937) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 17,992 | (11,559) |
| Deferred offering costs | 71,133 | 82,071 |
| Accounts payable | (576,277) | 749,660 |
| Accrued expenses | (2,935,920) | 161,963 |
| Net cash used in operating activities | (18,321,276) | (7,286,286) |
| Cash flows from investing activities: | ||
| Purchase of property and equipment | (19,171) | — |
| Net cash used in investing activities | (19,171) | — |
| Cash flows from financing activities: | ||
| Proceeds from the February 2024 Public Offering, net | 5,417,053 | — |
| Proceeds from the Class D Common Stock Warrants exercises | 241,390 | — |
| Proceeds from Warrant Inducement exercises, net | 3,501,276 | — |
| Proceeds from Class D Pre-Funded Warrants exercise | 127 | — |
| Proceeds from the Class E Common Stock Warrants exercises | 3,687,918 | — |
| Redemption of Series A Preferred Stock | — | (5,000) |
| Proceeds from the February 2023 Public Offering, net | — | 14,029,974 |
| Proceeds from Class C Pre-Funded Warrants exercise | — | 34 |
| Net cash provided by financing activities | 12,847,764 | 14,025,008 |
| Net (decrease) increase in cash and cash equivalents | (5,492,683) | 6,738,722 |
| Cash and cash equivalents at beginning of period | 11,991,701 | 5,252,979 |
| Cash and cash equivalents at end of period | $6,499,018 | $11,991,701 |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Fair Value of Class G Common Stock Warrants | $2,066,429 | $— |
| Fair Value of Class F Common Stock Warrants | $4,104,680 | $— |
| Fair Value of Class E Common Stock Warrants in connection with the Class D Warrant Inducement | $4,887,683 | $— |
| Incremental fair value of the Class D Common Stock Warrants in connection with the Class D Warrant Inducement | $939,679 | $— |
| Equity issuance costs in connection with the Class D Warrant Inducement included in accounts payable | $25,968 | $— |
| Fair Value of Class D Common Stock Warrants in connection with the February 2024 Public Offering | $6,269,684 | $— |
| Fair Value of Class C Common Stock Warrants in connection with the February 2023 Public Offering | $— | $13,996,500 |
| Alternative cashless exercise of Class C Common Stock Warrants | $57,589 | $5,526,287 |
| Deferred offering costs included in accounts payable and accrued expenses | $— | $66,033 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.